Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.58 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1308762 | 1.00 | FOLH1 (0.58) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL29371190 | 1.00 | FOLH1 (0.58) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL29617647 | 1.00 | FOLH1 (0.58) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL29860303 | 0.97 | FOLH1 (0.55) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL29759596 | 0.95 | FOLH1 (0.57) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL1243885 | 0.95 | FOLH1 (0.57) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL1243890 | 0.95 | FOLH1 (0.57) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL30584460 | 0.95 | FOLH1 (0.57) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL23876142 | 0.95 | FOLH1 (0.51) | FOLH1GSRGNPATCPB2ERAP2 | |
| SCHEMBL21645322 | 0.95 | FOLH1 (0.51) | FOLH1GSRGNPATCPB2ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-3448417-B1 | INSULIN DIMER-INCRETIN CONJUGATES | MERCK SHARP & DOHME LLC (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4615487-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| CN-120053661-A | Hydrophilic fatty acid complex for preventing, preventing or treating microbial infection, preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120053660-A | Hydrophilic complex for preventing, preventing or treating microbial infection, preparation and application thereof | 太阳雨林(北京)生物医药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119855607-A | Carbon chain substance for regulating transmembrane transport and fluidity of cell membrane, preparation and application | 太阳雨林(北京)生物医药有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4520348-A1 | CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF | Sunforest (Beijing) Biopharma Ltd (CN) | 2025-03-12 | — | — | EP | disclosed |
| US-20240424109-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4436610-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024102633-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-1392484-A4 | HIGH THROUGHPUT SCREENING OF CRYSTALIZATION OF MATERIALS | CALIFORNIA INST OF TECHN (US) | 2004-07-28 | — | — | EP | disclosed |
| US-6752991-B1 | Nucleic acids encoding a house dust mite allergen Der p III, and uses therefor | IMMULOGIC PHARMACEUTICAL CO. | 2004-06-22 | — | — | US | disclosed |
| US-20040115731-A1 | Microfluidic protein crystallography | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2004-06-17 | — | — | US | disclosed |
| EP-1392484-A2 | HIGH THROUGHPUT SCREENING OF CRYSTALIZATION OF MATERIALS | California Institute of Technology (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030061687-A1 | High throughput screening of crystallization materials | CALIFORNIA INSTITUTE OF TECHNOLOGY, A CALIFORNIA CORPORATION | 2003-04-03 | — | — | US | disclosed |
| WO-2002082047-A2 | HIGH THROUGHPUT SCREENING OF CRYSTALLIZATION OF MATERIALS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-10-17 | — | — | WO | disclosed |
| US-6180771-B1 | GIVEN NUCLEOTIDE SEQUENCE; USEFUL FOR PHARMACEUTICAL ADMINISTRATION OR METHODS OF DIAGNOSING SENSITIVITY TO HOUSE DUST MITES | IMMULOGIC PHARMACEUTICAL CORP. | 2001-01-30 | — | — | US | disclosed |
| EP-0733064-A1 | NUCLEIC ACIDS ENCODING A HOUSE DUST MITE ALLERGEN, $i(DER P) III, AND USES THEREFOR | IMMULOGIC PHARMACEUTICAL CORPORATION (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015976-A1 | NUCLEIC ACIDS ENCODING A HOUSE DUST MITE ALLERGEN, DER P III, AND USES THEREFOR | IMMULOGIC PHARMACEUTICAL CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
| US-4256632-A | ANTICAREINOGENIC AGENTS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | INSR, GPR119, GLP1R | FOLH1 368/4885GSR 231/4885GNPAT 1396/4885 |
| US-20240424109-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | GPR119, INSR, IAPP | FOLH1 544/4885GSR 2313/4885GNPAT 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.